Trump Signs Executive Order to Fast-Track FDA Reviews of Psychedelic Drugs Following Joe Rogan Lobbying
President Trump signed an executive order on April 18 or 19, 2026, directing the FDA to expedite reviews of psychedelic drugs designated as breakthrough therapies for treating PTSD, depression, addiction, and mental health issues, especially for veterans.
The order tasks FDA with issuing priority review vouchers to psychedelics like serotonin 2A agonists (e.g., psilocybin, MDMA) and facilitates fast rescheduling upon approval.
It establishes pathways for patient access to investigational psychedelics, naming ibogaine for opioid dependence and veteran TBI treatment.
Podcaster Joe Rogan attended the Oval Office signing with RFK Jr. and Dr. Mehmet Oz, after texting Trump data on ibogaine and discussing it with RFK Jr.
Companies like Compass Pathways welcomed the order for accelerating psilocybin approval; $50 million allocated for state-level ibogaine research.